For a 79-year-old patient taking apixaban (Eliquis) who is scheduled for cystoscopy‑guided right ureteroscopy with laser lithotripsy and stent placement, how long should the apixaban be held before the procedure?

Hold Apixaban for 48 Hours Before Ureteroscopy with Laser Lithotripsy

For this 79-year-old patient undergoing cystoscopy-guided right ureteroscopy with laser lithotripsy and stent placement, apixaban (Eliquis) should be held for 48 hours (2 days) before the procedure.

Rationale for 48-Hour Hold

Ureteroscopy with laser lithotripsy is classified as an intermediate-to-high bleeding risk procedure where surgical hemostasis cannot be easily controlled and bleeding could have significant clinical consequences. The FDA label for Eliquis explicitly states that the drug "should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding" 1.

This recommendation is strongly supported by multiple international guidelines:

• Canadian Cardiovascular Society (2014): Recommends interrupting apixaban 2-3 days before procedures with intermediate or high bleeding risk 2
• French Working Group on Perioperative Hemostasis (2017): Specifies that high hemorrhagic risk procedures require stopping apixaban for 2-3 days (48-72 hours) before surgery 3
• American Heart Association/ACC (2014): States that procedures requiring complete hemostasis need discontinuation for ≥48 hours in patients with normal renal function 4

Critical Considerations for This 79-Year-Old Patient

Renal Function Assessment is Essential

You must check this patient's creatinine clearance (CrCl) immediately using the Cockcroft-Gault formula. The 48-hour hold applies only if renal function is normal (CrCl >50 mL/min).

• If CrCl 30-50 mL/min: Extend the hold to 72 hours (3 days) 3
• If CrCl <30 mL/min: Consider extending to 96 hours (4 days) and obtain hematology consultation 3

The patient's age (79 years) places them at higher risk for reduced renal clearance, making this assessment non-negotiable.

Drug Interactions Matter

Check if the patient is taking P-glycoprotein inhibitors (e.g., verapamil, amiodarone, dronedarone) or strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir), as these can increase apixaban levels and may require extending the discontinuation period 3, 1.

No Bridging Anticoagulation Required

Do not bridge with heparin or LMWH during the 48-hour interruption period. Multiple guidelines explicitly state that bridging is not needed for DOACs like apixaban due to their rapid offset kinetics 2, 3, 2. Bridging should only be considered in extremely high thrombotic risk patients (CHADS₂ score ≥3, mechanical heart valve, stroke/TIA within 3 months, rheumatic heart disease) 2.

Timing of Last Dose

The last dose of apixaban should be taken 48 hours before the scheduled procedure time. For example:

• If surgery is scheduled for 8:00 AM on Friday, the last dose should be taken at 8:00 AM on Wednesday
• Since apixaban is dosed twice daily, this means skipping 4 consecutive doses

Verification Before Procedure

Recent evidence suggests that measuring apixaban levels pre-procedure can provide additional safety assurance. A 2022 prospective study found that 94% of patients achieved clinically insignificant apixaban concentrations (≤30 ng/mL) after 48-hour discontinuation 5. If available at your institution, consider checking an anti-Xa level or apixaban concentration on the morning of surgery, particularly given this patient's age.

Resumption After Procedure

Resume apixaban 48-72 hours after the procedure once adequate hemostasis is established 2. The FDA label states to restart "as soon as adequate hemostasis has been established" 1. For ureteroscopy specifically:

• Wait until gross hematuria has resolved or is minimal
• Ensure no active bleeding from the surgical site
• Start with the patient's usual dose (no need for reduced initial dosing)
• Do not use prophylactic LMWH during this gap unless the patient has extremely high thrombotic risk

Recent real-world evidence from Chinese urologists shows that ureteroscopy can be performed safely in anticoagulated patients, with continuation strategies being increasingly adopted by experienced surgeons 6, 7. However, given the lack of robust prospective data and the intermediate-high bleeding risk classification, the conservative 48-hour hold remains the evidence-based standard.

Common Pitfalls to Avoid

1. Don't assume normal renal function in a 79-year-old—always calculate CrCl
2. Don't bridge with heparin unless extreme thrombotic risk exists
3. Don't resume too early—wait for hemostasis confirmation, typically 48-72 hours post-op
4. Don't forget to document the exact timing of the last dose and communicate this clearly to the surgical team
5. Don't use INR or aPTT to assess apixaban levels—these tests are unreliable for DOACs 8